Mitteilungen der Deutschen Gesellschaft für Pathologie

    This is a preview of subscription content, access via your institution.

    Literatur

    1. 1.

      Rikova K et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190–1203

      CAS  Article  Google Scholar 

    2. 2.

      Bergethon K et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–870

      CAS  Article  Google Scholar 

    3. 3.

      Heydt C et al (2019) Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors. J Mol Diagn 21(6):971–984

      CAS  Article  Google Scholar 

    4. 4.

      Warth A et al (2014) ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology 65(2):187–194

      Article  Google Scholar 

    5. 5.

      Doebele RC et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21(2):271–282

      CAS  Article  Google Scholar 

    6. 6.

      Drilon A et al (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378(8):731–739

      CAS  Article  Google Scholar 

    7. 7.

      Drilon A et al (2020) Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 21(2):261–270

      CAS  Article  Google Scholar 

    8. 8.

      Shaw AT et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21):1963–1971

      Article  Google Scholar 

    9. 9.

      Facchinetti F et al (2016) Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Clin Cancer Res 22(24):5983–5991

      CAS  Article  Google Scholar 

    10. 10.

      Katayama R et al (2019) The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun 10(1):3604

      Article  Google Scholar 

    11. 11.

      Papadopoulos KP et al (2020) U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 26(18):4785–4794

      CAS  Article  Google Scholar 

    12. 12.

      Cui M et al (2020) Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Mol Oncol 14(11):2787–2795

      Article  Google Scholar 

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Mitteilungen der Deutschen Gesellschaft für Pathologie. Pathologe 42, 140–142 (2021). https://doi.org/10.1007/s00292-020-00883-9

    Download citation